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We aimed to evaluate the feasibility of using streptavidin–biotin-based pretargeting for 
positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active 
tumors. 
Procedures 
We used POS, a genetically engineered form of streptavidin that selectively stabilizes in 
HIF-1-active cells, and (4-18F-fluorobenzoyl)norbiotinamide (18F-FBB), a radiolabelled biotin 
derivative, for performing a biodistribution study and for PET imaging. The tumoral 18F-FBB 
accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α 
immunohistochemical signal. 
Results 
18F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85% ± 0.55% 
injected dose/g at 3h), and clear PET images were obtained at the same time point. The 
tumoral 18F-FBB accumulation positively correlated with luciferase bioluminescence (R = 
0.72, P < 0.05), and most of the area showing 18F-FBB accumulation corresponded to 
HIF-1α-positive areas. 
Conclusion 
Pretargeting with POS and 18F-FBB is an effective approach for PET imaging of HIF-1-active 
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 Introduction 
Abnormal rapid growth of tumor cells outstrips the blood supply, which develops an 
oxygen tension below physiologic levels (hypoxia) [1]. It appears to be strongly associated 
with malignant progression and the development of radioresistance [2, 3]. The transcription 
factor hypoxia-inducible factor-1 (HIF-1) has been reported to be one of the critical 
components of hypoxic responses [4]. Because HIF-1 was recently reported to be closely 
related to tumor malignancy and to hinder both chemotherapy and radiation therapy [5, 6], 
noninvasive imaging of HIF-1-active hypoxic tumor cells may be useful in making a 
qualitative diagnosis and establishing a therapy for cancer. The oxygen-sensitive alpha 
subunit of HIF-1 (HIF-1α) contains an oxygen-dependent degradation domain (ODD) and 
regulates the HIF-1 activity by inducing the degradation of HIF-1 via the ODD under 
normoxic conditions [7]. Therefore, it is likely that a probe that contains the ODD and 
induces degradation in a similar manner as HIF-1α does can be used to evaluate HIF-1 
activity in vivo. 
We have recently synthesized proteins in which the protein transduction domain 
(PTD) is fused to the ODD and demonstrated that these proteins were efficiently delivered to 
hypoxic regions and were stabilized in HIF-1-active cells [8-11]. We have also fused the PTD 
and the ODD with a monomeric streptavidin (SAV) to produce a chimeric protein, 
PTD-ODD-SAV (POS), and synthesized a radiolabelled biotin derivative, 
(3-123/125Iiodobenzoyl)norbiotinamide (123/125I-IBB). POS was degraded in an 
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oxygen-dependent manner, and a clear image of the tumor was obtained at 24 h after the 
injection of 123I-IBB-conjugated-POS of which accumulation in the tumor was found to 
correlate with the HIF-1 activity [12]. Furthermore, we were able to obtain the tumor image 
rapidly by using of a pretargeting approach. The adequate-contrast image was obtained just 6 
h after injection of 123I-IBB in the pretargeting approach, while 24 h was required in the case 
using 123I-IBB-conjugated-POS [13]. 
Compared to single-photon emission computed tomography imaging, positron 
emission tomography (PET) imaging is more sensitive and more quantitative, and provides 
images with higher spatial resolution. The limited and heterogenous expression of HIF-1 in 
the tumor required a high-spatial-resolution device for the accurate imaging of 
HIF-1-expressed regions. Therefore, we attempted to obtain PET images of the HIF-1-active 
hypoxic tumors by using POS. Since it required 24 h to obtain the adequate image using 
directly-radiolabeled POS [12], we adopted the prertargeting approach to reduce radiation 
exposure. 
Fluorine-18 is one of the most widely used positron emitters because of its adequate 
half-life, ease of production, and low positron energy; hence, a 18F-labeled biotin derivative 
may be useful in PET imaging. However, there have been few reports of the application of 
such a molecule in pretargeted imaging [14]. Therefore, we synthesized 
(4-18F-fluorobenzoyl)norbiotinamide (18F-FBB) in order to perform PET studies with POS. 
This study aimed to evaluate the feasibility of using POS and 18F-FBB for pretargeted PET 
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imaging of HIF-1-active areas in tumors. 
 
 
Materials and Methods 
Synthesis of 18/19F-FBB 
N-Succinimidyl-4-fluorobenzoate (SFB, compound 2) was synthesized according to 
a previously described method [15]. The detailed method of FBB (compound 3) synthesis has 
been described in the supplemental materials. 
The synthesis of 18F-FBB (18F-3) is outlined in Fig. 1. Fluorine-18 was produced via 
the 18O(p,n)18F nuclear reaction by using a proton beam current to irradiate 18O-H2O [16, 17]. 
18F-SFB (18F-2) was synthesized according to a previously described method [18, 19] and 
obtained with decay-uncorrected radiochemical yield of 30–40%. 18F-SFB was then 
concentrated under a stream of nitrogen and added to a solution of N,N’-dimethylformamide 
(DMF):water (4:1); the DMF solution contained norbiotinamine hydrochloride (5 mg/mL). 
NEt3 was added to make the solution basic. The reaction was performed at room temperature 
for 0.5–1 h, and the reaction mixture was loaded onto a C18 Sep-Pak cartridge (Waters, 
Milford, MA). The C18 cartridge was eluted with water and then with acetonitrile. The 
acetonitrile fraction was evaporated, and the residue was purified using high-performance 
liquid chromatography (HPLC) (Cosmosil 5C18MS-II column; Nacalai Tesque, Kyoto, Japan; 
25% acetonitrile; flow rate, 1 mL/min). The retention time of 18F-FBB was 11 min. The 
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radiochemical purity was measured using HPLC, and the specific activity was determined on 
the basis of the ultraviolet (UV) absorbance at 254 nm. The solvent was removed by rotary 
evaporation and reconstituted in water or saline for use in in vitro and in vivo studies. 
 
Preparation of fusion protein 
POS was overexpressed in Escherichia coli and purified as described in a previous 
report [12]. Purified POS was dissolved in Tris-HCl buffer (pH 8.0). 
 
Binding of POS and 18F-FBB 
18F-FBB, D-biotin (0–500 pmol), and POS (0.04 pmol) were mixed and incubated in 
100 mM citrate buffer (pH 5.0) for 1 h at 37°C. The binding of 18F-FBB to POS in the 
absence of D-biotin was detected using size-exclusion chromatography (PD-10; GE 
Healthcare Bioscience, Uppsala, Sweden). The reaction mixture containing D-biotin was 
applied to an Amicon Microcon filter (Millipore) and centrifuged at 4500 × g for 30 min at 
4°C (Micro Cooling Centrifuge 1720; Kubota, Osaka, Japan). The radioactivities of the 
reactant and filtrate (unbound 18F-FBB) were measured, and the binding rate was calculated. 
All measurements were performed in triplicate. 
 
Cell and cell culture 
FM3A mouse mammary tumor cells were purchased from Health Science Research 
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Resources Bank (Osaka, Japan). Suit2 human pancreatic tumor cells were originally obtained 
from American Type Culture Collection (Manassas, VA). Suit2/5HRE-CMVmp-Luciferase 
(Suit2/Luc) cells that express luciferase in response to HIF-1 activity were established and 
supplied by Prof. Kizaka-Kondoh [20]. Both the cell types were cultured using a previously 
reported method [12, 13].  
 
Animal model 
Animal studies were conducted in accordance with our institutional guidelines, and 
the experimental procedures were approved by the Kyoto University Animal Care Committee. 
Female C3H/He mice and BALB/c nu/nu mice at 5 weeks of age were purchased from Japan 
SLC, Inc. (Hamamatsu, Japan). Models of FM3A and Suit2/Luc tumors were prepared as 
described in a previous report [12]. After tumor implantation, mice were fed an 
AIN76-A-based, biotin-free diet (Oriental Yeast Co. Ltd., Tokyo, Japan) in order to prevent 
dietary biotin from inhibiting the binding of 18F-FBB to POS. The mice were subjected to a 
tracer study at 2–3 weeks after the implantation. The average diameter and average volume of 
the tumors were approximately 10 mm and 500 mm3, respectively. 
 
Biodistribution 
18F-FBB (370 kBq) was injected intravenously into FM3A-implanted mice (n = 
4–5); the mice were sacrificed at 0.5, 1, 3, and 6 h after the injection. For the pretargeting 
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study, we used the protocol that has been previously reported as an optimal method [13]. The 
mice (n = 4–5) were intravenously injected with 30 μg of POS; after 24 h, 18F-FBB (370 kBq) 
was injected intravenously. The mice were sacrificed at the same time points as mentioned 
above. Whole organs were immediately obtained and weighed, and their radioactivity was 
measured. The results were expressed in terms of the percent injected dose per gram of tissue 
(%ID/g). 
 
In vivo blocking study 
FM3A-implanted mice (n = 4) were pretargeted with POS (30 μg); after 23.5 h, the 
mice were injected with a vehicle or saline solution of D-biotin (1 nmol). After another 30 
min, 18F-FBB (370 kBq) was administered and 3 h later, the mice were sacrificed. Whole 
organs were immediately removed and weighed, and their radioactivity was measured. The 
results were expressed as %ID/g. 
 
18F-FBB accumulation vs. HIF-1 transcriptional activity in tumors in mice pretargeted with 
POS 
Some Suit2/Luc-implanted mice (n = 8) were pretargeted with 30 μg of POS. After 
24 h, 18F-FBB (370 kBq for 5 mice and 18.5 MBq for 3 mice) was administered intravenously. 
For immunohistochemical analysis, the mice that received the higher dose of 18F-FBB were 
intraperitoneally injected with pimonidazole (PIMO, 60 mg/kg) 1 h after the 18F-FBB 
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injection. Further 2.5 h after the 18F-FBB injection, 200 μL D-luciferin solution (10 mg/mL in 
PBS; VivoGlo Luciferin, Promega, WI) was injected intraperitoneally. After 20 min, the mice 
were anesthetized with 2.5% isoflurane, and bioluminescence imaging was performed using 
IVIS Spectrum System (Xenogen, Alameda, CA). The signal intensity within the tumors was 
analyzed using Living Image 3.0 software (Xenogen). The mice were sacrificed 3 h after the 
18F-FBB injection, the radioactivity of the tumors was measured, and the results were 
expressed in terms of %ID. The tumor specimens obtained from the mice injected with the 
higher dose of 18F-FBB were subjected to an autoradiographic study. 
Another set of Suit2/Luc-implanted mice (n = 4) were pretargeted with 30 μg of POS. 
After 24 h, 18F-FBB (18.5 MBq) was administered intravenously and 6 h later, the 
bioluminescence signal and radioactivity were compared using the procedure described above. 
After the radioactivity measurement, the tumor specimens were subjected to metabolite 
analysis. 
 
Size-exclusion analysis of radioactivity in tumors 
After bioluminescence imaging, each mouse was anesthetized with 2.5% isoflurane, 
and urine was collected from its bladder. The mice were then sacrificed, and their tumors 
were immediately removed. Extracts were prepared using a previously reported method [13], 
with a slight modification. In brief, the tumors were homogenized in ice-cold 0.1 M Tris-HCl 
buffer containing 1% sodium dodecylsulfate and 0.15 M NaC1 (pH 6.5), by using a Polytron 
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homogenizer (PT10-35; Kinematica AG, Switzerland). The preparations were then 
centrifuged at 4°C and 4,600 × g for 20 min. The supernatants and urine were analyzed by 
size-exclusion chromatography with a PD-10 column.  
 
Autoradiography 
Autoradiographic studies were performed on the same mice used for the 
bioluminescence imaging (n = 3). Ten μm-thick frozen tumor sections were prepared 
according to a previously reported procedure [21]. The sections were exposed to imaging 
plates (BAS-SR; Fuji Photo Film Co., Ltd., Tokyo, Japan) for 3 h, and autoradiograms were 
then obtained and analyzed as previously described [21], except that BAS5000 was used 
instead of BAS3000 (both scanners, Fuji Photo Film Co., Ltd.).  
 
Immunohistochemical analysis 
The adjacent 10 μm-thick sections used in the autoradiographic study were subjected 
to dual fluorescent immunostaining for HIF-1α and PIMO according to a previously 
described method [13]. In brief, the sections were fixed, blocked, and treated with 
anti-human/mouse HIF-1α polyclonal antibody (R&D Systems, Minneapolis, MN), as a 
primary antibody. The specific signals were detected using an Alexa Fluor 568-conjugated 
F(ab′)2 fragment of goat anti-rabbit antibody (Invitrogen, San Diego, CA). Thereafter, the 
sections were washed with PBS and treated with fluorescein isothiocyanate 
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(FITC)-conjugated mouse IgG1 monoclonal antibody (Chemicon, Temecula, CA) according 
to the manufacturer’s protocol for PIMO staining. The sections were then dried and 
coverslipped using an antifade reagent (ProLong Gold with DAPI; Invitrogen). Another 
adjacent section was stained with hematoxylin–eosin (HE). Fluorescent and bright-field 




18F-FBB (22.2 ± 6.7 MBq) was injected into the tail veins of FM3A-implanted mice 
(n = 6) 24 h after they were pretargeted with POS (30 μg). The mice were anesthetized with 
2.5% isoflurane and placed on a scanner bed in the prone position. At 3 h after the injection, 
the mice were imaged for 15 min by using eXplore VISTA (GE Healthcare Bioscience). An 
energy window of 250–700 keV was used. Before reconstruction, the raw data were corrected 
for random and scattered coincidences, and radioactive decay. Attenuation correction was not 
performed. PET images were reconstructed according to a standard filtered back-projection 
procedure (FBP) with a Ramp filter (alpha, 1.0; cutoff, 1.0) or by using a two-dimensional 
ordered-subset expectation maximization algorithm (2D-OSEM; iterations, 2; subsets, 16). 
The regions of interest (ROIs) were drawn on the tumor and the corresponding area in the left 




The two groups were compared using the Mann–Whitney U test, and correlation 
coefficients were assessed using the Spearman rank analysis. Values of P < 0.05 were 




Radiosynthesis of 18F-FBB 
The decay-uncorrected radiochemical yield from 18F-SFB as a starting material was 
38%; radiochemical purity, >95%; total synthesis time, 70–100 min; and specific activity at 
the end of synthesis, >97 GBq/μmol (limit of detection). 
 
Binding of POS and 18F-FBB 
After the incubation of 18F-FBB with POS, the radioactivity was detected at 
macromolecular fraction, as determined using size-exclusion chromatography; this indicated 
that 18F-FBB bound to POS (data not shown). The binding of 18F-FBB to POS was not 
inhibited by D-biotin at concentrations <100 nM (binding rate, 99.7% ± 0.2%), whereas it 
was completely inhibited by 1000 nM D-biotin (binding rate, 6.0% ± 1.3%); the results of 
inhibition study are similar to those using 18F-FBB alone (5.5% ± 0.5%), i.e., in the case of 




An examination of the biodistribution of 18F-FBB alone revealed that both the 
tumor-to-blood and the tumor-to-muscle ratios were less than 1 at all time points. This 
indicated that 18F-FBB did not accumulate in the tumors. Moreover, 18F-FBB was rapidly 
cleared from all organs, except the intestine (Table 1). In contrast, in the pretargeted group, 
tumor accumulation of 18F-FBB 3 h after injection was 2.85% ± 0.55% ID/g, which was more 
than 20-fold than for 18F-FBB alone (0.11% ± 0.10% ID/g) (Table 2). The tumor-to-blood and 
tumor-to-muscle ratios were greater than 1 as early as 30 min after the injection, and both 
these ratios increased in a time-dependent manner because of the rapid clearance of 18F-FBB 
from the body. Although 18F-FBB accumulation in the kidneys and intestine was high, the 
radioactivity in the other normal tissues showed a more rapid decrease than in the tumor 
(Table 2). Pretreatment with D-biotin markedly decreased 18F-FBB accumulation (80%) in the 
tumors (Table 3). The 18F-FBB accumulation in the other tissues also decreased following 
treatment with D-biotin. 
 
18F-FBB accumulation vs. HIF-1 transcriptional activity in tumors in mice pretargeted with 
POS 
A significant positive correlation was observed between HIF-1-induced luciferase 
bioluminescence and 18F-FBB accumulation 3 h after injection in tumors in mice pretargeted 
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with POS (R = 0.72, P < 0.05; Fig. 3). A similar correlation was also observed at 6 h after the 
injection (R = 0.70, P < 0.05, data not shown). 
 
Size-exclusion analysis of radioactivity in tumors 
The recovery of radioactivity from the tumor samples was 94% ± 7.4%, and that 
from the PD-10 columns was 98% ± 14%. A major proportion of the radioactivity was eluted 
in a macromolecular fraction (79% ± 5.8%, n = 4).  
Urine analysis was performed using 2 samples, because the quantity of urine 
obtained from 2 mice was too small. In the case of the urine samples, the recovery of 
radioactivity from the PD-10 columns was 92% and 99%. More than 99% of the radioactivity 
of both samples was eluted in a small-molecule fraction.  
 
PET imaging 
The high-resolution PET imaging of the mice clearly showed the tumors implanted 
in the right thigh (Fig. 4). The calculated tumor-to-muscle ratio was 3.4 ± 1.4. 
 
Histology, autoradiography, and immunohistochemistry 
HE staining revealed the presence of necrotic areas in the tumor (Fig. 5A). 
PIMO-positive areas were located in the center of the section, surrounding the necrotic core 
(Fig. 5B), whereas HIF-1α-positive areas were present peripherally (Fig. 5C). The 
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autoradiogram showed that the distribution of 18F-FBB in the POS-pretargeted tumor was 
heterogeneous (Fig. 5D). Most of the 18F-FBB-accumulated areas corresponded to the 




The most important aspect of the present study was to evaluate whether the 
accumulation of 18F-FBB in POS-pretargeted tumors reflects the level of HIF-1 expression or 
activity. For this purpose, we compared 18F-FBB accumulation with HIF-1 transcriptional 
activity and HIF-1 immunohistochemical signal among tumors in the same animals that 
expressed the HIF-1-dependent luciferase reporter gene. In the tumors in the mice pretargeted 
with POS, the accumulated radioactivity at both 3 and 6 h after the administration of 18F-FBB 
significantly correlated with the luciferase bioluminescence, i.e., the HIF-1 activity. 
Furthermore, the tumor-to-blood ratios at 3 and 6 h were also similar. On the basis of these 
results, we performed the PET-imaging study at 3 h after the injection of 18F-FBB, because 
imaging in the early phase after probe injection is preferred in order to avoid radioactive 
decay and to reduce radiation exposure. The PET images showed the heterogeneous 
intratumoral distribution of 18F-FBB in the mice pretargeted with POS; this result would 
reflect the HIF-1-active regions because the intratumoral HIF-1-active regions have been 
reported to be heterogeneous [22]. In fact, the majority of 18F-FBB-accumulated areas 
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corresponded to the HIF-1α-positive areas observed on autoradiography. Therefore, these 
findings indicate that PET imaging with POS pretargeting and the use of 18F-FBB can help 
detect intratumoral HIF-1-active regions. These findings are in accordance with those of our 
previous study where 123I-IBB was used instead of 18F-FBB [13]. Because the lipophilicity of 
18F-FBB is lower than that of 123I-IBB, 18F-FBB showed faster blood clearance and a higher 
tumor-to-blood ratio within a short duration after the injection.  
Some hypoxia-imaging probes—such as 18F-fluoromisonidazole (18F-FMISO), 
1-α-D-(5-deoxy-5-18F-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA), and 
64Cu-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM)—have been developed [23, 
24]. These probes can detect low oxygen pressures (less than 10 mmHg), and are useful in 
predicting the efficacy of radiotherapy [25]. In the present study, the distribution pattern of 
18F-FBB in the POS-pretargeted tumor was different from that in the PIMO-positive areas. 
This result is somewhat different from that obtained in our previous studies where 125I-IBB, 
which was used in the pretargeting study, and 125I-IPOS were mainly distributed near the 
PIMO-positive areas [12, 13]. One reason for this discordant result may be the difference in 
the tumor models used. Suit2 pancreatic tumor cells were used for the autoradiographic and 
histological analyses in the present study, whereas MDA-MB-231 mammary tumor cells were 
used in the case of the 125I-IPOS study [12]. Another reason could be the difference in tumor 
size. The tumor volume used in the present study was approximately 1.5 times greater than 
that used in the 125I-IBB study [13]. In fact, even with the same tumor model, similarity 
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between the distribution patterns of HIF-1α- and PIMO-positive areas depended on the tumor 
size; these areas were adjacently located in small tumors but had a different distribution 
pattern in large tumors [26]. Oh et al. reported that 64Cu-ATSM accumulated on the surface of 
the tumor, whereas PIMO-positive areas located in the center [27]. This finding is similar to 
that obtained in the present study on 18F-FBB distribution patterns in POS-pretargeted 
tumors; however the researchers have not determined HIF-1α expression in the tumor model 
used in their study. A direct comparison between the POS/18F-FBB system and other hypoxia 
imaging probes will help clarifying the differences in the characteristics of the tumor cells 
existed in each area where probe accumulation was observed, and in the information obtained 
from each image. 
The basic requirements of an effective biotin derivative for the pretargeting approach 
include stability against metabolism in vivo, rapid clearance from the circulation, and a 
binding affinity to (strept)avidin. The first-generation radiolabeled biotin derivatives were 
easily degraded by biotinidase [28]. Biotinidase-mediated degradation can be stopped by 
creating a reversed amide bond (i.e., NH−CO bond) between the valeryl chain of biotin and 
the prosthetic group [29]. On the basis of these reports, we decided to convert the terminal 
carboxylic group of biotin into a primary amine. We found that 18F-FBB stably existed in 
mouse plasma (data shown in the supplemental materials), indicating that this compound was 
resistant to degradation by biotinidase. The results of the biodistribution study revealed that 
the accumulated radioactivity in the bone was low and that it did not increase in a 
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time-dependent manner. These results suggest that 18F-FBB is resistant to defluorination in 
vivo. Furthermore, 18F-FBB was rapidly cleared from the blood. 18F-FBB bound to POS and 
the binding was inhibited by D-biotin both in vitro and in vivo. These results indicate that 
18F-FBB meets the basic requirements of an effective biotin derivative for use in the 
pretargeting approach. 
We found that 18F-FBB accumulated in the POS-pretargeted tumors. Further, this 
accumulation was inhibited by D-biotin and a major proportion of the radioactivity of the 
tumor was attributable to macromolecules. Taken together, these results indicate that the 
intratumoral radioactivity was caused by the binding of 18F-FBB to the SAV moiety of POS. 
Thus, we concluded that 18F-FBB can bind streptavidin not only in vitro but also in vivo. The 
amount of 18F-FBB accumulation in the tumor was not as high as that of 18F-FDG [30]; this 
finding could have been due to the limited expression of HIF-1. The expression of HIF-1 is 
not ubiquitous, but heterogeneous, and is small in tumors [31]. In fact, radioligand 
accumulation in tumors harboring HIF-1-dependent reporter genes has been reported to range 
from 1% to 2% ID/g in previous studies [31-33]. Furthermore, the amount of 18F-FBB 
accumulation was similar to that of other hypoxia-imaging probes such as 18F-FMISO and 
64Cu-ATSM (2–5% ID/g) [30, 34, 35]. 
In the pretargeted group, some abdominal organs showed higher radioactivity 
accumulation than the tumor. The high background activity in the abdominal region hampers 
the evaluation of the HIF-1 activity in the abdomen and pelvis, and further modification is 
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required for such an evaluation. The radioactivity of the liver and kidneys may be attributable 
to the high accumulation of POS in these tissues [12]. Pretreatment of D-biotin decreased 
18F-FBB accumulation in the liver and kidneys, suggesting that not all the POS in these 
tissues was degraded or cleared within 24 h. The slow rate of degradation is a drawback of 
using POS. Optimization of the interval between the POS and 18F-FBB administration is 
necessary when imaging HIF-1-active regions in the liver and kidneys. On the other hand, the 
radioactivity in the intestine was not blocked by D-biotin pretreatment. It is reported that 
biotinidase, which is involved in the transport of biotin, exists in the intestine [36]. Thus, 
radioactivity accumulation in the intestine would reflect the behavior of 18F-FBB itself, and 
not its binding to POS. In this case, the biotin derivatives that show faster clearance from the 




We have developed a novel radiolabeled biotin derivative, 18F-FBB, and confirmed 
its ability to bind to the streptavidin moiety both in vitro and in vivo. 18F-FBB accumulated in 
the tumors pretargeted with POS; these tumors were clearly visualized on PET imaging. The 
accumulation of 18F-FBB significantly correlated with the HIF-1 transcriptional activity, and 
the intratumoral distribution of 18F-FBB corresponded to HIF-1α-positive areas in the tumors 
pretargeted with POS. These findings suggest that POS and 18F-FBB are potent probes for the 
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PET imaging of HIF-1-active areas in tumors. 
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Table 1. Biodistribution of 18F-FBB in FM3A-implanted mice. 
 
Time after injection (h) 










1.68 ± 0.19 
12.07 ± 1.11 
10.19 ± 1.14 
17.99 ± 1.92 
1.38 ± 0.60 
2.08 ± 0.23 
1.14 ± 0.96 
0.83 ± 0.39 
0.66 ± 0.26 
0.86 ± 0.12 
7.30 ± 1.24 
6.42 ± 0.75 
21.12 ± 7.27 
0.77 ± 0.29 
1.70 ± 0.74 
1.54 ± 0.52 
0.90 ± 0.30 
0.66 ± 0.71 
0.10 ± 0.07 
0.44 ± 0.06 
0.42 ± 0.07 
7.72 ± 1.15 
0.11 ± 0.10 
0.09 ± 0.06 
0.27 ± 0.20 
0.64 ± 0.20 
0.95 ± 0.61 
0.04 ± 0.01 
0.24 ± 0.11 
0.24 ± 0.12 
3.72 ± 1.81 
0.05 ± 0.03 
0.13 ± 0.08 
0.20 ± 0.17 
0.94 ± 0.30 
0.36 ± 0.37 
Organ uptake values are expressed as the percent injected dose per gram of tissue, except in 
the case of the tumor/blood and tumor/muscle ratios. Values are represented as the mean ± 
SD. n = 4–5 
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Table 2. Biodistribution of 18F-FBB in FM3A-implanted mice pretargeted with POS. 
Organ uptake values are expressed as the percent injected dose per gram of tissue, except in 
the case of the tumor/blood and tumor/muscle ratios. Values are represented as the mean ± 
SD. n = 4–5 
 
Time after injection (h) 










2.79 ± 0.57 
15.02 ± 2.05 
21.59 ± 3.24 
12.68 ± 2.60 
4.65 ± 0.49 
2.49 ± 0.71 
2.82 ± 0.26 
1.73 ± 0.47 
1.98 ± 0.54 
1.54 ± 0.47 
12.69 ± 1.86 
19.52 ± 2.71 
13.68 ± 2.52 
4.70 ± 0.97 
2.55 ± 1.21 
3.92 ± 2.42 
3.16 ± 0.59 
2.18 ± 0.75 
0.56 ± 0.16 
5.74 ± 1.18 
9.22 ± 1.92 
5.95 ± 1.57 
2.85 ± 0.55 
0.93 ± 0.40 
1.27 ± 0.42 
5.36 ± 1.32 
3.93 ± 2.50 
0.57 ± 0.22 
3.76 ± 0.51 
4.87 ± 0.99 
1.64 ± 0.51 
2.48 ± 0.49 
0.29 ± 0.15 
0.91 ± 0.22 
4.91 ± 2.04 
9.51 ± 3.31 
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Table 3. Blocking study of the biodistribution of 18F-FBB in FM3A-implanted mice 
pretargeted with POS. 










0.66 ± 0.06 
3.58 ± 1.00 
3.39 ± 1.05 
6.59 ± 2.76 
2.06 ± 0.29 
0.28 ± 0.04 
1.50 ± 1.37 
4.00 ± 2.38 
7.29 ± 0.94 
0.22 ± 0.10* 
1.48 ± 0.67* 
0.80 ± 0.41* 
7.90 ± 0.98 
0.34 ± 0.14* 
0.14 ± 0.06* 
1.31 ± 0.38 
1.63 ± 0.19* 
2.53 ± 1.19** 
Organ uptake values are expressed as the percent injected dose per gram of tissue, except in 
the case of the tumor/blood and tumor/muscle ratios. Values are represented as the mean ± 










Synthesis of FBB (3) and 18F-FBB (18F-3). (i) N,N,N',N'-Tetramethyl-O- 
(N-succinimidyl)uranium tetrafluoroborate, CH3CN, 90°C, 10 h. (ii) Norbiotinamine, NEt3, 
DMF:H2O (4:1), r.t., 5 h. (iii) Norbiotinamine, NEt3, DMF:H2O (4:1), r.t., 1 h. 
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Binding of 18F-FBB to POS. The black columns represent the mean calculated binding rate of 
18F-FBB and POS in the presence of various concentrations of D-biotin. The white column 
represents the calculated binding rate of 18F-FBB alone, which indicates non-specific 
absorption to the column. D-biotin (1000 nM) significantly inhibited 18F-FBB binding to POS 
compared to the binding in the other D-biotin-treated group (*P < 0.05). 
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Correlation between the 18F-FBB accumulation at 3 h post-injection and HIF-1 activity within 
a tumor pretargeted with POS. The ordinate represents accumulated radioactivity (%ID), and 
the abscissa represents HIF-1-induced luciferase bioluminescence. The correlation coefficient 
(R) was 0.72, indicating a highly significant correlation (P < 0.05). 
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Typical PET images of FM3A-implanted mice. The mice were pretargeted with POS, and 24 
h later, they were intravenously injected with 18F-FBB. Images were acquired 3 h after the 
18F-FBB injection and reconstructed using 2D-OSEM. Tumors can be clearly visualized in 







Representative images of HE staining (A), PIMO immunostaining (B), HIF-1α 
immunostaining (C), and autoradiography (D). 
 
 
 
